+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Ursodeoxycholic Acid and Its Taurine- or Glycine-Conjugated Species Reduce Colitogenic Dysbiosis and Equally Suppress Experimental Colitis in Mice

Ursodeoxycholic Acid and Its Taurine- or Glycine-Conjugated Species Reduce Colitogenic Dysbiosis and Equally Suppress Experimental Colitis in Mice

Applied and Environmental Microbiology 83(7):

The promising results seen in studies of secondary bile acids in experimental colitis suggest that they may represent an attractive and safe class of drugs for the treatment of inflammatory bowel diseases (IBD). However, the exact mechanism by which bile acid therapy confers protection from colitogenesis is currently unknown. Since the gut microbiota plays a crucial role in the pathogenesis of IBD, and exogenous bile acid administration may affect the community structure of the microbiota, we examined the impact of the secondary bile acid ursodeoxycholic acid (UDCA) and its taurine or glycine conjugates on the fecal microbial community structure during experimental colitis. Daily oral administration of UDCA, tauroursodeoxycholic acid (TUDCA), or glycoursodeoxycholic acid (GUDCA) equally lowered the severity of dextran sodium sulfate-induced colitis in mice, as evidenced by reduced body weight loss, colonic shortening, and expression of inflammatory cytokines. Illumina sequencing demonstrated that bile acid therapy during colitis did not restore fecal bacterial richness and diversity. However, bile acid therapy normalized the colitis-associated increased ratio of Firmicutes to Bacteroidetes Interestingly, administration of bile acids prevented the loss of Clostridium cluster XIVa and increased the abundance of Akkermansia muciniphila, bacterial species known to be particularly decreased in IBD patients. We conclude that UDCA, which is an FDA-approved drug for cholestatic liver disorders, could be an attractive treatment option to reduce dysbiosis and ameliorate inflammation in human IBD.IMPORTANCE Secondary bile acids are emerging as attractive candidates for the treatment of inflammatory bowel disease. Although bile acids may affect the intestinal microbial community structure, which significantly contributes to the course of these inflammatory disorders, the impact of bile acid therapy on the fecal microbiota during colitis has not yet been considered. Here, we studied the alterations in the fecal microbial abundance in colitic mice following the administration of secondary bile acids. Our results show that secondary bile acids reduce the severity of colitis and ameliorate colitis-associated fecal dysbiosis at the phylum level. This study indicates that secondary bile acids might act as a safe and effective drug for inflammatory bowel disease.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 060446978

Download citation: RISBibTeXText

PMID: 28115375

DOI: 10.1128/aem.02766-16

Related references

Changes in hepatic gene expression upon oral administration of taurine-conjugated ursodeoxycholic acid in ob/ob mice. Plos one 5(11): E13858, 2010

An anti-inflammatory mechanism of taurine conjugated 5-aminosalicylic acid against experimental colitis: taurine chloramine potentiates inhibitory effect of 5-aminosalicylic acid on IL-1beta-mediated NFkappaB activation. European Journal of Pharmacology 618(1-3): 91-97, 2009

Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosis. Hepatology 29(2): 320-327, 1999

Unconjugated, glycine-conjugated, taurine-conjugated bile acid nonsulfates and sulfates in urine of young infants with cholestasis. Acta Paediatrica Scandinavica 73(3): 392-397, 1984

Ursodeoxycholic acid is conjugated with taurine to promote secretin-stimulated biliary hydrocholeresis in the normal rat. Plos one 6(12): E28717, 2011

Comparative effect of ursodeoxycholic acid and its glycine and taurine conjugates on the hepatocellular mobilization and efflux of calcium. Hepatology 16(4 Part 2): 253A, 1992

Bile acid glycine and taurine conjugates in serum of patients with primary biliary cirrhosis effect of ursodeoxycholic treatment. Gut 30(8): 1110-1115, 1989

On the quantitative determination of deoxycholic acid conjugated with glycine or taurine. Z NATURFORSCH 19b(6): 481-483, 1964

Production and characterization of group-specific monoclonal antibodies recognizing nonamidated, glycine- and taurine-amidated ursodeoxycholic acid 7-N-acetylglucosaminides. Journal of Steroid Biochemistry & Molecular Biology 64(3-4): 171-177, 1998

Effect of taurine-conjugated ursodeoxycholic acid on endoplasmic reticulum stress and apoptosis induced by advanced glycation end products in cultured mouse podocytes. American Journal of Nephrology 28(6): 1014-1022, 2008

High-performance liquid chromatographic mass spectrometric method for the determination of ursodeoxycholic acid and its glycine and taurine conjugates in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 798(2): 295-302, 2003

Tissue taurine content, activity of taurine synthesis enzymes and conjugated bile acid composition of taurine-deprived and taurine-supplemented rhesus monkey infants at 6 and 12 mo of age. Journal of Nutrition 121(6): 854-862, 1991

Glycine and taurine conjugation of ursodeoxycholic acid urso excreted into bile during infusion of unconjugated urso in rat. Journal of Hepatology 13(Suppl. 2): S170, 1991

Rabbit gallbladder inflammation is associated with a decreased glycine taurine conjugated bile acid ratio. Gastroenterology 98(5 Part 2): A256, 1990

Biliary secretion of ursodeoxycholic acid udca taurine and glycine conjugates sulfates and glucuronides in patients with external biliary drainage. Hepatology 14(4 Part 2): 260A, 1991